Founded Year

2018

Stage

Grant - II | Alive

Total Raised

$530M

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

-3 points in the past 30 days

About Tessera Therapeutics

Tessera Therapeutics focuses on genome engineering and genetic medicine. The company specializes in a technology that enables the writing of therapeutic messages into the human genome to address diseases. Tessera Therapeutics is also developing tissue-targeted non-viral delivery systems to facilitate genomic alterations. It was founded in 2018 and is based in Cambridge, Massachusetts.

Headquarters Location

55 Cambridge Parkway Suite 800E

Cambridge, Massachusetts, 02142,

United States

857-356-4700

Loading...

Loading...

Expert Collections containing Tessera Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Tessera Therapeutics is included in 2 Expert Collections, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

1,309 items

D

Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

Latest Tessera Therapeutics News

Tessera Therapeutics to Present New Preclinical Data From In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting

Nov 3, 2025

Location: Orange County Convention Center, West Halls B3-B4 About Tessera Therapeutics Tessera Therapeutics is pioneering a new approach to genome engineering through the development of its Gene Writing™ and delivery platforms, with the aim to unlock broad new therapeutic frontiers. Our Gene Writing platform is designed to write therapeutic messages into the genome by efficiently changing single or multiple DNA base pairs, precisely correcting insertions and deletions, or adding exon-length sequences and whole genes. Our proprietary lipid nanoparticle delivery platform is designed to enable the in vivo delivery of RNA to targeted cell types. We believe our Gene Writing and delivery platforms will enable transformative genetic medicines to not only cure diseases that arise from errors in a single gene, but also modify inherited risk factors for common diseases and create engineered cells to treat cancer and potentially autoimmune and other diseases. Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. For more information about Tessera, please visit www.tesseratherapeutics.com. Contact

Tessera Therapeutics Frequently Asked Questions (FAQ)

  • When was Tessera Therapeutics founded?

    Tessera Therapeutics was founded in 2018.

  • Where is Tessera Therapeutics's headquarters?

    Tessera Therapeutics's headquarters is located at 55 Cambridge Parkway, Cambridge.

  • What is Tessera Therapeutics's latest funding round?

    Tessera Therapeutics's latest funding round is Grant - II.

  • How much did Tessera Therapeutics raise?

    Tessera Therapeutics raised a total of $530M.

  • Who are the investors of Tessera Therapeutics?

    Investors of Tessera Therapeutics include Advanced Research Projects Agency for Health, Bill & Melinda Gates Foundation, Alaska Permanent Fund, SoftBank, Altitude Life Science Ventures and 18 more.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.